FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

10/11/24 9:31:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FBLG alert in real time by email

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O'Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

[email protected]

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697

[email protected]

Get the next $FBLG alert in real time by email

Date	Price Target	Rating	Analyst
10/30/2024	$12.00	Buy	H.C. Wainwright
9/24/2024	$12.00	Buy	Maxim Group

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Chat with this insight

Recent Analyst Ratings for
$FBLG

$FBLG
SEC Filings

SEC Form 10-Q filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update, Other Events

FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$FBLG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

SEC Form 4 filed by Director Link Matthew

SEC Form 4 filed by Director Hoffman Robert E.

$FBLG
Leadership Updates

Live Leadership Updates

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG
Press Releases

Fastest customizable press release news feed in the world

$FBLG
Market Insights

Live Market Insights

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

FibroBiologics Highlights Preliminary Proof-Of-Concept For Novel Artificial Thymus Organoid Technology

FibroBiologics Files Prospectus Relates To Resale Of Up To 16M Shares Of Common Stock By GEM

FibroBiologics To Join Russell 2000 Index; Effective July 1 Following Annual Reconstitution

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Chat with this insight

Recent Analyst Ratings for $FBLG

$FBLG SEC Filings

SEC Form 10-Q filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update, Other Events

FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$FBLG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

SEC Form 4 filed by Director Link Matthew

SEC Form 4 filed by Director Hoffman Robert E.

$FBLG Leadership Updates

Live Leadership Updates

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG Press Releases

Fastest customizable press release news feed in the world

$FBLG Market Insights

Live Market Insights

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

FibroBiologics Highlights Preliminary Proof-Of-Concept For Novel Artificial Thymus Organoid Technology

FibroBiologics Files Prospectus Relates To Resale Of Up To 16M Shares Of Common Stock By GEM

FibroBiologics To Join Russell 2000 Index; Effective July 1 Following Annual Reconstitution

Recent Analyst Ratings for
$FBLG

$FBLG
SEC Filings

$FBLG
Insider Purchases

$FBLG
Insider Trading

$FBLG
Leadership Updates

$FBLG
Analyst Ratings

$FBLG
Press Releases

$FBLG
Market Insights